Thursday, January 23, 2020, San Francisco, California, 6:15 PM – 8:45 PM

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Colorectal, Gastroesophageal and Pancreatic Cancer

Part 1 of a 2-Part CME Symposia Series

InterContinental San Francisco
888 Howard Street
San Francisco, CA 94103
Hotel Phone: (415) 616-6500

5:45 PM – 6:15 PM — Registration and Dinner Buffet
6:15 PM – 8:45 PM — Educational Meeting

Meeting Room
Grand Ballroom (Third Floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Crystal Denlinger, MD
Chief, GI Medical Oncology
Director, Survivorship Program
Deputy Director, Phase 1 Program
Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Howard S Hochster, MD
Distinguished Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director
Clinical Research
Director, Clinical Oncology Research
RWJBarnabas Health
New Brunswick, New Jersey

John L Marshall, MD
Chief, Hematology and Oncology
Director, Ruesch Center for the
Cure of GI Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Michael J Overman, MD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Philip A Philip, MD, PhD, FRCP
Kathryn Cramer Endowed Chair in
Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospital Leuven
Leuven, Belgium

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2020 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2020 Gastrointestinal Cancers Symposium.

Meeting Agenda and Format

To begin each module, results of interactive audience polling using networked iPads will be juxtaposed with the findings from a survey comprising case-based and related management questions completed by 25 clinical investigators prior to the meeting. Each faculty member will then deliver a presentation reviewing recently published research data and ongoing clinical trials related to the topics and questions addressed via the surveys. After each presentation, moderated panel discussion will take place to generate other relevant perspectives and dialogue.

MODULE 1: The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers — Dr Hochster

  • Design, eligibility criteria and primary and secondary endpoints evaluated in the Phase III BEACON CRC trial comparing encorafenib/cetuximab with or without binimetinib to irinotecan/cetuximab or FOLFIRI/cetuximab for patients with mCRC with BRAF V600E tumor mutations
  • Key efficacy findings from BEACON CRC; improvement in overall survival associated with encorafenib/binimetinib/cetuximab
  • Frequency and severity of toxicities observed with encorafenib/binimetinib/cetuximab in BEACON CRC; rates of treatment discontinuation due to tolerability issues
  • Optimal integration of targeted therapy into the management of mCRC with a BRAF V600E tumor mutation
  • Available data with and ongoing investigation of novel HER2-directed approaches (eg, lapatinib/trastuzumab, pertuzumab/trastuzumab, tucatinib/trastuzumab, pertuzumab/T-DM1, trastuzumab deruxtecan) for patients with mCRC
  • Other genomic abnormalities observed in patients with mCRC and current research efforts to therapeutically exploit these potential targets

MODULE 2: Lingering Questions in the Selection and Sequence of Therapy for Patients with mCRC — Dr Marshall

  • Published research data exploring the correlation between tumor location and response to specific therapeutic interventions
  • Key efficacy outcomes from the Phase II regorafenib dose optimization study (ReDOS); effect of findings on optimal dosing strategies for regorafenib
  • Optimal sequencing of regorafenib, TAS-102 and EGFR antibody therapy for patients with mCRC; use of clinical characteristics to inform this decision
  • Available data with and potential role of TAS-102 in combination with other systemic agents in mCRC or in earlier disease stages
  • Mechanism of action of and early efficacy findings with napabucasin for patients with mCRC; design, eligibility and estimated completion date of the Phase III CanStem303C study evaluating napabucasin in combination with FOLFIRI for previously treated mCRC

MODULE 3: Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Overman

  • Indications for microsatellite instability (MSI) assessment in mCRC; benefits and limitations of available testing platforms
  • Available research findings guiding the FDA approvals of nivolumab, pembrolizumab and nivolumab/ipilimumab for patients with MSI-high/mismatch repair-deficient mCRC; patient selection for anti-PD-1 monotherapy versus combined anti-PD-1/anti-CTLA-4 antibody therapy
  • Biologic rationale for the investigation of regorafenib in combination with nivolumab for patients with microsatellite-stable mCRC
  • Key efficacy and safety outcomes from the Phase Ib REGONIVO trial evaluating regorafenib/nivolumab for patients with mCRC or metastatic gastric cancer; development plans for this combination
  • Ongoing clinical trials evaluating immune checkpoint inhibitors alone and in combination with other systemic approaches for patients with early and advanced CRC

MODULE 4: Optimal Management of Metastatic Gastric/Gastroesophageal Cancer — Dr Denlinger

  • Design, eligibility criteria and key efficacy and safety findings from the Phase III KEYNOTE-062 trial evaluating pembrolizumab alone and in combination with chemotherapy as first-line treatment for advanced gastric/gastroesophageal junction (GEJ) cancer; current role of immune checkpoint inhibition for patients with metastatic gastric/GEJ cancer
  • Early experience and ongoing research efforts with anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic agents for patients with metastatic gastric/GEJ cancer
  • Primary and secondary endpoints achieved in the Phase III TAGS study of TAS-102 for heavily pretreated metastatic gastric cancer
  • FDA approval of and patient selection for TAS-102 in metastatic gastric cancer
  • Results from the Phase III KEYNOTE-181 trial and FDA approval of pembrolizumab for progressive, PD-L1-positive advanced esophageal cancer
  • Key efficacy and safety findings from the Phase III ATTRACTION-3 trial comparing nivolumab to chemotherapy for unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of previous chemotherapy

MODULE 5: Contemporary Treatment Approaches for Patients with Pancreatic Cancer — Dr Philip

  • Use of contemporary chemotherapy regimens (mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
  • Outcomes from the Phase III Unicancer GI PRODIGE 24/CCTG PA.6 trial comparing adjuvant mFOLFIRINOX to gemcitabine for resected PAD
  • Key efficacy results and clinical implications of the Phase III APACT trial evaluating adjuvant nab paclitaxel/gemcitabine versus gemcitabine alone
  • Published research experience with, patient selection for and practical integration of nanoliposomal irinotecan (nal-IRI) for relapsed metastatic PAD
  • Available data with and ongoing evaluation of nal-IRI in earlier disease settings

MODULE 6: PARP Inhibition in Pancreatic Cancer; Promising Investigational Strategies — Prof Van Cutsem

  • Design and eligibility criteria for the randomized Phase III POLO trial evaluating olaparib versus placebo as maintenance therapy for patients with metastatic PAD and a germline BRCA mutation whose disease has not progressed on first-line platinum-based chemotherapy
  • Key efficacy and safety findings from POLO; achievement of primary progression-free survival endpoint with olaparib
  • Most common adverse events reported among patients receiving olaparib in the POLO trial; incidence of Grade ≥3 toxicities and treatment discontinuation
  • FDA approval of maintenance olaparib for patients with metastatic PAD and a germline BRCA mutation after platinum-based chemotherapy; implications for genetic testing and routine practice
  • Promising agents or strategies under investigation for early and advanced PAD

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer, considering biomarker profile (eg, BRAF, MSI status), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Use the results of biomarker assessments (eg, HER2, PD-L1 status), clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric, gastroesophageal and esophageal cancer.
  • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
  • Recall the biologic rationale for, published research data with and ongoing research evaluating the use of immune checkpoint inhibitors alone or in combination with chemotherapy, targeted agents or other immunotherapies in the management of colorectal, gastric and pancreatic cancer, and identify patients who may be eligible for this strategy in or outside of a clinical trial setting.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with novel and recently approved systemic therapies for patients with locally advanced or metastatic colorectal, gastric and pancreatic cancer to support quality of life and continuation of therapy.
  • Appraise available and emerging data with other investigational agents currently in clinical testing for colorectal, gastric and pancreatic cancer, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Array BioPharma Inc, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Merck, Seattle Genetics, and Taiho Oncology Inc.

InterContinental San Francisco
888 Howard Street
San Francisco, CA 94103
Hotel Phone: (415) 616-6500

Meeting Room
Grand Ballroom (Third Floor)

The InterContinental San Francisco hotel is adjacent to the Moscone Center, where the 2020 Gastrointestinal Cancers Symposium is taking place.


Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:45 PM on Thursday, January 23rd. If you are interested in attending, please visit our registration desk outside the Grand Ballroom (third floor) of the InterContinental San Francisco hotel (888 Howard Street) near the Moscone Convention Center.

We will accept onsite registration on a first come, first served basis but with priority given to clinicians in practice. Please note, onsite registration does not guarantee participation in the session or meal service.

If you have any questions, please feel free to contact us via email at or call (800) 233-6153.

Registration for this event is independent of registration for the Gastrointestinal Cancers Symposium.